Skip to main content
Year archive

Compugen Ltd. — 2025 filings

All 58 regulatory filings released by Compugen Ltd. (CGEN) in 2025, sourced directly from the official regulator.

58 Filings
2025 Period
2025 filings (58)
Filing Released Lang
6k-Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
Capital/Financing Update
2025-12-17 English
6k-Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
Regulatory Filings
2025-12-17 English
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
Regulatory Filings
2025-12-17 English
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
Regulatory Filings
2025-12-17 English
Reports Third Quarter 2025 Results
Earnings Release Q3 2025
2025-11-10 English
Reports Third Quarter 2025 Results
Report Publication Announcement
2025-11-10 English
Compugen to Participate in Stifel 2025 Healthcare Conference
Regulatory Filings
2025-11-04 English
Compugen to Participate in Stifel 2025 Healthcare Conference
Report Publication Announcement
2025-11-04 English
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
Report Publication Announcement
2025-10-27 English
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
Report Publication Announcement Q3 2025
2025-10-27 English
Immediate Report
Regulatory Filings
2025-10-14 English
Immediate Report
Regulatory Filings
2025-10-14 English
Other Report or Announcement
Regulatory Filings
2025-10-13 English
Other Report or Announcement
Regulatory Filings
2025-10-13 English
Other Report or Announcement
Regulatory Filings
2025-10-06 English
Other Report or Announcement
Report Publication Announcement
2025-10-06 English
RESULTS OF A MEETING HELD ON AUGUEST 6, 2025
AGM Information
2025-09-17 English
RESULTS OF A MEETING HELD ON AUGUEST 6, 2025
Regulatory Filings
2025-09-17 English
to Present Research at the Single Cell Genomics 2025 Conference
Regulatory Filings
2025-09-08 English
to Present Research at the Single Cell Genomics 2025 Conference
Regulatory Filings
2025-09-08 English
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Regulatory Filings
2025-08-28 English
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Regulatory Filings
2025-08-28 English
Immediate Report of Meeting to be held on September 16, 2025
Proxy Solicitation & Information Statement
2025-08-06 English
Immediate Report of Meeting to be held on September 16, 2025
Proxy Solicitation & Information Statement
2025-08-06 English
Compugen Reports Second Quarter 2025 Results
Interim / Quarterly Report Q2 2025
2025-08-06 English
Compugen Reports Second Quarter 2025 Results
Report Publication Announcement
2025-08-06 English
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
Regulatory Filings
2025-07-28 English
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025
Regulatory Filings
2025-07-28 English
to Release Second Quarter 2025 Results on Wednesday, August 6, 2025, conference call at 8:30 AM ET
Report Publication Announcement
2025-07-23 English
to Release Second Quarter 2025 Results on Wednesday, August 6, 2025, conference call at 8:30 AM ET
Report Publication Announcement
2025-07-23 English
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer
Regulatory Filings
2025-07-21 English
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer
Report Publication Announcement
2025-07-21 English
Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences
Regulatory Filings
2025-06-12 English
Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences
Report Publication Announcement
2025-06-12 English
Compugen Reports First Quarter 2025 Results
Earnings Release Q1 2025
2025-05-19 English
Compugen Reports First Quarter 2025 Results
Report Publication Announcement
2025-05-19 English
Leadership Transitions Effective September 2025
Regulatory Filings
2025-05-13 English
Leadership Transitions Effective September 2025
Report Publication Announcement
2025-05-13 English
Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025, conference call at 8:30 AM ET
Report Publication Announcement
2025-05-05 English
Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025, conference call at 8:30 AM ET
Report Publication Announcement
2025-05-05 English
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025
Regulatory Filings
2025-03-26 English
Compugen to Participate in Multiple Virtual Investor Conferences in April 2025
Report Publication Announcement
2025-03-26 English
FORM 20-F- For the fiscal year ended December 31, 2024
Annual Report FY 2024
2025-03-04 English
FORM 20-F- For the fiscal year ended December 31, 2024
Report Publication Announcement
2025-03-04 English
Form 6-K- Fourth Quarter and Full Year 2024 Results
Earnings Release Q4 2024
2025-03-04 English
Form 6-K- Fourth Quarter and Full Year 2024 Results
Report Publication Announcement
2025-03-04 English
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference
Regulatory Filings
2025-03-03 English
Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference
Report Publication Announcement
2025-03-03 English
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, UnigenTM with Ultima Genomics’ Single Cell Genomics Sequencing Technology
Regulatory Filings
2025-02-26 English
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, UnigenTM with Ultima Genomics’ Single Cell Genomics Sequencing Technology
Report Publication Announcement
2025-02-26 English
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025,conference call at the same day at 08:30 am ET
Report Publication Announcement
2025-02-18 English
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025,conference call at the same day at 08:30 am ET
Report Publication Announcement
2025-02-18 English
Form SCHEDULE 13G/A 1- BRISTOL MYERS SQUIBB CO
Major Shareholding Notification
2025-02-15 English
Form SCHEDULE 13G/A 1- BRISTOL MYERS SQUIBB CO
Regulatory Filings
2025-02-15 English
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Report Publication Announcement
2025-02-04 English
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Report Publication Announcement
2025-02-04 English
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
Regulatory Filings
2025-01-08 English
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
Report Publication Announcement
2025-01-08 English